Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Obesity drug liraglutide tested on teens in Real-World study

NCT ID NCT07304141

Knowledge-focused Sponsor: Göteborg University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 128 teens aged 10-18 with obesity who were prescribed liraglutide (Saxenda) in Sweden. Researchers looked at changes in BMI and metabolic health over time. The goal is to see how the drug performs outside of controlled trials, in everyday clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Liraglutide (Saxenda)
What this could lead to
If successful, this could help doctors better understand how liraglutide works for teens with obesity in everyday care, potentially improving treatment guidelines.
What could go wrong
This is a small, retrospective study that only looks back at existing data, so it cannot prove cause and effect. Results may not apply to all teens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

128 people

The number who actually took part.

Started

Dec 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children at the Pediatric Clinic, Region Halland, and at the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital.

Ages

10 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adolescents aged 10-18 years with obesity who were offered pharmacological treatment * Provided consent to participate * Participants with short treatment duration, early adverse effects, or who proceeded to surgery are also included in baseline data Exclusion Criteria: * Hypothalamic obesity * Craniopharyngioma * Syndromic obesity / monogenic obesity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Child obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Pediatric Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Child obesity Obesity (disorder)

Contacts and locations

Locations

  • the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital.

    Gothenburg, 416 50, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.